Uveal melanoma patient attitudes towards prognostic testing using gene expression profiling.

Area of Science:

• Ophthalmology
• Oncology
• Genetics

Background:

• Uveal melanoma is the most common primary intraocular cancer in adults.
• Accurate prognostic information is crucial for guiding treatment decisions and managing patient anxiety.
• Molecular prognostic testing, such as the 15-gene expression profile (GEP) test, offers valuable insights into tumor behavior.

Purpose of the Study:

• To explore patient experiences and decision regret following molecular prognostic testing for uveal melanoma.
• To assess the perceived value of the 15-gene expression profile (GEP) test in uveal melanoma management.

Main Methods:

• Retrospective, cross-sectional survey study.
• Online questionnaire administered to uveal melanoma patients who underwent prognostic biopsy/molecular testing.
• Analysis of patient-reported experiences, value derived from testing, and decision regret.

Main Results:

• 90% of respondents desired prognostic information at diagnosis.
• 99% of patients who shared their 15-GEP test results reported gaining value from the test.
• Patients who received prognostic testing experienced significantly lower decision regret compared to those who opted out.
• Decision regret levels did not vary based on the GEP classification (high- or low-risk).

Conclusions:

• Uveal melanoma patients generally desire prognostic testing.
• The 15-gene expression profile (GEP) test is perceived as valuable by patients, irrespective of the risk classification.
• Prognostic testing may contribute to reduced decision regret in uveal melanoma patients.